<DOC>
	<DOCNO>NCT00930241</DOCNO>
	<brief_summary>This study prospective randomize trial compare twice daily daily administration basic immunosuppressive regimen lung transplant patient .</brief_summary>
	<brief_title>Twice Daily Versus Once Daily Administration Tacrolimus Lung Transplantation</brief_title>
	<detailed_description>Prevalence data non-compliance solid organ transplantation fluctuate report 39 % transplant recipient ( z . B. lung transplantation 13 - 22 % ; Kugler et al. ) . Non-compliance immunosuppressive therapy associate increase risk late-acute rejection development chronic transplant dysfunction . Chronic transplant dysfunction ( bronchiolitis obliterans- syndrome-BOS ) second cause organ failure first year follow lung transplantation often lead re-transplantation death . Preventative procedure improve compliance simplification dose immunosuppressant ( daily dose instead twice daily dose ) , prescription immunosuppressant less side-effects raise patient´s awareness great responsibility efficacy therapy . Prospective study metaanalysis reveal probability good compliance double daily administration comparison twice daily best predictor good compliance easy therapy . For reason want investigate extent profit lung transplant patient receive daily basis immunosuppression comparison receive twice daily dose . Hypothesis : Patients daily administration group immunosuppressive medication well compliance compare twice daily group ( measure endpoint variability medication abstraction electronic device )</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients ( Pts ) 1 year single lung , double lung heart/lung transplantation Pts treat cyclosporin , steroid MMF Pts ≥ 18 ≤ 70 year Pts one following : pt recurrent acute rejection ( RAR ) two acute rejection 3 month ( first 3 year post Tx , 6 month ( &gt; 3 year post Tx ) define : transbronchial biopsy &gt; A1 ( A1 clinical criterion ) nach ISHLT ( B &gt; 1R ) decline FEV1 &gt; 10 % baseline exclusion infection , airway complication , effusion etc . improvement steroidpulse therapy ( methylprednisolone 15 mg/kg three day ) = FEV1 improvement &gt; 10 % compare last measurement AR treatment Pts steroidresistant ongoing acute rejection ( OAR ) define : transbronchial biopsy &gt; A1 ( A1 clinical criterion ) least 4 week follow steroidpulse therapy ( methylprednisolone 15 mg/kg three day ) FEV1 improvement ( &lt; 5 % baseline ) least 14 day follow ACR steroidpulse therapy ( methylprednisolone 15 mg/kg three day ) exclusion infection , airway complication , effusion etc . Pts new onset BOS ( nBOS ) Unexplained FEV1 &lt; 80 % baseline exclusion Infection , airway complication , effusion etc Pts CyA associate side effect ( e.g. , hyperlipidaemia , hypertriglyceridemia , hypertension , hirsutism , gingival hyperplasia ) Pregnant breast feed woman Pts use doublebarrier method birth control Pts systemic infection Pts severe diarrhea , vomit , active ulcer Pts severe liver disease liver cirrhosis Pts mTor inhibitor Pts hypersensitivity Tacrolimus , macrolides tablet ingredient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Lung Transplantation</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Deterioration graft function</keyword>
</DOC>